Tadeusz RobakHuiqiang HuangJie JinJun ZhuTing LiuOlga SamoilovaHalyna PylypenkoGregor VerhoefNoppadol SiritanaratkulEvgenii OsmanovJuliana PereiraJiri MayerXiaonan HongRumiko OkamotoLixia PeiBrendan RooneyHelgi van de VeldeFranco CavalliMedical University of LodzSun Yat-Sen University Cancer CenterZhejiang University School of MedicineBeijing Cancer HospitalWest China Hospital of Sichuan UniversityLobachevsky State University of Nizhni NovgorodnullKU Leuven– University Hospital LeuvenMahidol UniversityN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesUniversidade de Sao Paulo - USPFakultni Nemocnice BrnoFudan University Shanghai Cancer CenterTokyo Metropolitan Komagome HospitalJanssenJanssen Research and DevelopmentTakeda OncologyOspedale San Giovanni2018-12-212019-03-142018-12-212019-03-142017-06-05Leukemia and Lymphoma. (2017), 1-810292403104281942-s2.0-85020251694https://repository.li.mahidol.ac.th/handle/20.500.14594/41858© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients for whom stem cell transplantation was not an option. This post hoc subanalysis of the VR-CAP data from LYM-3002 evaluated the effect of bortezomib dose intensity on OS in patients who completed ≥6 cycles of treatment. From the end of cycle 6, patients receiving ≥4.6 mg/m2/cycle of bortezomib had significantly longer OS (but not PFS) compared with those receiving <4.6 mg/m2/cycle by univariate analysis (HR 0.43 [95% CI: 0.23–0.80]; p = .0059). This association remained significant in multivariate analysis adjusting for baseline patient and disease characteristics (HR 0.40 [95% CI: 0.20–0.79]; p = .008]. Higher bortezomib dose intensity was the strongest predictor of OS in newly diagnosed MCL patients receiving VR-CAP. Clinicaltrials.gov identifier: NCT00722137.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticle in PressSCOPUS10.1080/10428194.2017.1321750